Medical artificial intelligence (AI) company Lunit (CEO Seo Beom-seok) announced on the 18th that it has signed a strategic partnership with global diagnostic and clinical trial service company Labcorp for collaboration in the field of AI-based digital pathology.
The two companies recently formalized their collaboration by announcing their first joint research results at the 2025 Society for Immuno-Oncology (SITC 2025) and the 2025 American Society for Molecular Pathology (AMP 2025), both held in the United States. Headquartered in North Carolina, Labcorp is a leading global diagnostic and clinical trial services company with a market capitalization of $22.1 billion and annual revenue of $13 billion. Its 70,000 employees in over 100 countries perform over 700 million diagnostic tests annually.
This collaboration aims to combine Labcorp's clinical and pathological expertise with Lunit's AI algorithms to improve tumor microenvironment analysis and accelerate the discovery of biomarkers that can predict immuno-oncology drug responses.
The companies' first joint study identified tumor microenvironmental characteristics by MET mutation type in non-small cell lung cancer (NSCLC). At SITC 2025, Lunit Scope IO was used to analyze pathology slides from 371 patients, including those with MET exon 14 deletions, MET amplification, and no MET mutations, and to evaluate immunotherapy response. At AMP 2025, the same technology was used to identify differences in the tumor microenvironment by MET mutation type and to observe differences in treatment response.
This study confirmed the potential of AI-based digital pathology technology to contribute to immuno-oncology research, and the two companies plan to expand their collaboration to large-scale research based on real-world data and other cancer types in the future.
“Our collaboration with Labcorp will be a significant stepping stone for AI technology to be utilized in oncology clinical settings,” said Seo Beom-seok, CEO of Lunit. “The combination of AI and digital pathology will be a key driving force in connecting research insights to actual treatment decisions.”
“Our collaboration with Lunit will allow us to derive clinical value from vast amounts of pathology data,” said Shakti Ramkisoon, chief medical officer of Labcorp’s oncology division. “We have confirmed that AI-based digital pathology technology can accurately identify tumor characteristics and contribute to the development of personalized treatment strategies.”
- See more related articles
You must be logged in to post a comment.